Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indisulam plus capecitabine in metastatic colorectal cancer
2004-002597-33Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of indisulam and capecitabine in colorectal cancer (CRC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Tumour response, Progression-free survival and 3 more. Started Jan 2005; status: completed.
02
Drugs
indisulamcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2004-002597-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002597-33.